NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners

Leerink Partners analyst Roanna Ruiz raised the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) to $45.00 (from $44.00) while maintaining a Outperform rating.

The analyst comments "NewAmsterdam (NAMS) reported a straightforward 3Q25 earnings that support our enthusiasm for the company's solid execution and steady advancement toward value-inflecting catalysts for their lead oral, dual LDL-C and Lp(a)-lowering asset, obicetrapib (obi). Based on our investor conversations, we see a few core drivers of NAMS stock's recent positive momentum: a) "rising tide" of investor excitement for biotech, b) increased large Pharma deal flow in cardiometabolic, and c) a "scarcity value" that benefits NAMS as one of the few meaningfully de-risked cardiovascular companies with multiple late stage Ph. 3 datasets in hand, with a lead asset (obi) that offers potential multiplexed lipid lowering benefits plus future upside in Alzheimer's. Looking ahead, we expect favorable readthrough to NAMS if NVS' [Not Rated] HORIZON Ph. 3 CV Outcomes (CVOT) trial reads out positively in 1H26, validating the Lp(a) lowering hypothesis, in our view. Regarding 3Q updates, we are most encouraged by: (1) the marketing authorization applications (MAAs) for obi and the fixed-dose-combination (FDC) of obi + ezetimibe were accepted by the EMA as of August, which we view as a nice "check the box"; (2) we like NAMS' steady execution across the clinical pipeline, with their PREVAIL CVOT on track for a 2H26/1H27 readout and REMBRANDT (plaque imaging Ph. 3) progressing to full enrollment; and (3) NAMS maintains a healthy balance sheet with $756M in cash and cash equivalents, which provides runway through the PREVAIL readout and supports regulatory & pre-commercial build-out. We updated our model for the 3Q25 print, which increased our PT to $45 (vs. $44 prior). Reit. OP."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49